Macquarie Group
TSBX

Macquarie Group’s Turnstone Biologics TSBX Stock Holding History

Macquarie Group’s Portfolio TSBX Stock Details TSBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-789
Closed -$2.07K – 1897
2024
Q2 		$2.07K Buy
+789
New +$2.25K ﹤0.01% 1800

Other funds holding TSBX

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
TPC
Takeda Pharmaceutical Company Tokyo, Japan $16.4M AUM 195.92% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
7IH
72 Investment Holdings Stamford, Connecticut $49.6M AUM 684.72% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return

Macquarie Group's TSBX Position: Q3 2024 in Review

Macquarie Group sold out of Turnstone Biologics (TSBX) in Q3 2024, closing a stake of 789 shares — an estimated $2.07K sold.

Macquarie Group first reported a position in TSBX in Q2 2024 and held it in 1 quarter. The position peaked at $2.07K in Q2 2024. 24 funds tracked by Wall St. Rank hold TSBX as of Q3 2024.

  • Macquarie Group reported no remaining Turnstone Biologics position as of Q3 2024 after selling out during the quarter.
  • Macquarie Group sold 789 Turnstone Biologics shares in Q3 2024, an estimated $2.07K.
  • Macquarie Group first reported a position in Turnstone Biologics in Q2 2024 and held it in 1 quarter.
  • Macquarie Group's Turnstone Biologics position peaked at $2.07K in Q2 2024.
  • 24 funds tracked by Wall St. Rank held Turnstone Biologics as of Q3 2024.

Based on Macquarie Group's 13F filing for Q3 2024, filed 14 Nov 2024.